EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2025.04.02

Essex Bio-Technology Reports Stellar 2024 Annual Results：Net Profit soars 11.6% to HK$ 307.2 Million, Dividend increases 33.3% Focuses on Strengthening R&D Capabilities and Expanding Market Access

2025.03.26

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Date

Title

2022-03-22

Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million

2021-12-20

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021-11-10

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-10-27

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

2021-08-12

Essex Bio-Technology Reports First Half 2021 Financial Results

2021-07-25

Essex Bio-Technology Listed on Two Authoritative Lists

2021-07-19

First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-04-30

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT